Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Participants will receive PegIntron injection pen (Peginterferon alfa-2b) and Rebetol
(Ribavirin) combination therapy as their usual medical treatment. The current study aims to
evaluate whether the previously introduced, and now widely accepted and implemented
educational program, which represents additional efforts in everyday practice to increase
patient compliance, will succeed in achieving adherence rate in treated participants similar
to the extent demonstrated by clinical trials.